A generic operational strategy to qualify translational safety biomarkers

Autor: Matheis, K, Laurie, D, Andriamandroso, C, Arber, N, Badimon, L, Benain, X, Bendjama, K, Clavier, I, Colman, P, Firat, H, Goepfert, J, Hall, S, Joos, T, Kraus, S, Kretschmer, A, Merz, M, Padro, T, Planatscher, H, Rossi, A, Schneiderhan-Marra, N, Schuppe-Koistinen, I, Thomann, P, Vidal, JM, Molac, B

Publikováno v: DRUG DISCOVERY TODAY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

The importance of using translational safety biomarkers that can predict, detect and monitor drug-induced toxicity during human trials is becoming increasingly recognized. However, suitable processes to qualify biomarkers in clinical studies have not

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::be1c63186fa9ab551e659bec57aa3dd1
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11873

A generic operational strategy to qualify translational safety biomarkers.

Autor: Matheis K; Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Padro T, Planatscher H, Rossi A, Schneiderhan-Marra N, Schuppe-Koistinen I, Thomann P, Vidal JM, Molac B

Publikováno v: Drug discovery today [Drug Discov Today] 2011 Jul; Vol. 16 (13-14), pp. 600-8. Date of Electronic Publication: 2011 May 06.